DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S.
biotech company developing pharmaceutical cannabis (marijuana) products, is very
pleased to announce a second patient suffering skin cancer is self-administering
cannabis extracts in collaboration with Cannabis Science. This patient has
photo-documented dramatic results that we will be release to the public once
treatment is completed and has been properly vetted by clinical biopsy. Cannabis
Science, in conjunction with several Colorado-licensed dispensaries and
physicians, consults with a number of cancer patients who were seeking to inform
themselves of the current peer-reviewed scientific literature, regarding modern
and historical use of cannabis preparations for treating cancers so that they
can make informed decisions regarding their self-directed cancer treatment.
Cannabis has an outstanding safety profile as determined in 1988 by Federal
Administrative Law Judge Francis Young who recommended cannabis be removed from
Schedule I. The refusal of the DEA to follow this recommendation has resulted in
16 states allowing some form of medical marijuana access for their citizens.
Numerous other states are moving in this direction. Consequently, patients in
states with medical marijuana laws are able to make an informed decisions to try
various state-legal cannabis preparations and to determine what is most
effective for their particular condition. As a result, there is an unprecedented
accumulation of “anecdotal” data
Currently, there are a variety treatments available for treating various skin
cancers including standard surgical excision (Mohs Surgery), chemotherapy,
radiation, and cryosurgery. Unfortunately for many, the cancer frequently
returns and requires additional treatments. Chemo and radiation therapy are
typically used by patients who aren’t candidates for surgery (i.e. where
surgical excision could disfigure or make it difficult to reconstruct the
excised area). If reoccurrence occurs, radiation therapy is often not repeated
as it may further damage the tissue lead to resistance.
While the above treatments may to be effective for many, few patients would
choose to go through surgical procedures, radiation, or chemotherapy if a better
alternative were available. Patients self-administering cannabis extracts in the
convenience of their own home appear to be effectively resolving their cancerous
lesions over a period of a few weeks to a few months.
Cannabis Science is committed to making cannabis-based medicines available to
the public as rapidly as possible. The Company is taking multiple approaches to
accomplishing this aim in the United States. The science of cannabinoids has
exploded over the past decade, laying the scientific foundation for the many
medicinal uses of this unique plant. Cannabinoids are a class of biologically
active compounds produced by all vertebrates (endocannabinoids) the Cannabis
plant (phytocannabinoids), and more recently patentable synthetic compounds
produced by chemists. Today’s modern peer-reviewed science supports the many
historical uses that were discovered over thousands of years of medicinal use by
Please visit www.cannabisscience.com
to view the “Breaking News” of the successful results and images of the
self-administered cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical
marijuana research and development. The second formulations will address the
needs of patients choosing to use concentrated cannabis extracts to treat their
ailments. Eventually, all Americans will have access to a safe and effective FDA
approved medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is scientifically
absurd. Cannabis medicines, with no effective lethal dose, are far safer than
aspirin, acetaminophen, and most other OTC drugs that kill thousands of
Americans every year.
The Company works with world authorities on phytocannabinoid science
targeting critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based pharmaceutical
products. In sum, we are dedicated to the creation of cannabis-based medicines,
both with and without psychoactive properties, to treat disease and the symptoms
of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act
of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur. Factors that
could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede / President
Investor Relations Management